Cyramza

Increased risk of hemorrhage; permanently discontinue if severe bleeding (Grade 3 or 4) occurs. Control hypertension prior to initiating. Monitor BP every 2 weeks or more frequently as indicated; withhold for severe hypertension until controlled. Monitor for infusion-related reactions during therapy. Have emergency resuscitative equipment available. Permanently discontinue if arterial thromboembolic events, severe uncontrolled hypertension (despite antihypertensives), hypertensive crisis or encephalopathy, Grade 3 or 4 infusion-related reactions, urine protein >3g/24hrs, nephrotic syndrome, or GI perforation occurs. Impaired wound healing: withhold for 28 days prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Clinical deterioration in patients with Child-Pugh B or C cirrhosis (eg, new or worsening encephalopathy, ascites, hepatorenal syndrome). Permanently discontinue if posterior reversible encephalopathy syndrome develops. Monitor proteinuria by urine dipstick and/or urinary protein creatinine ratio. Monitor thyroid function. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 3 months after last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 2 months after last dose).

Increased risk of hemorrhage; permanently discontinue if severe bleeding (Grade 3 or 4) occurs. Control hypertension prior to initiating. Monitor BP every 2 weeks or more frequently as indicated; withhold for severe hypertension until controlled. Monitor for infusion-related reactions during therapy. Have emergency resuscitative equipment available. Permanently discontinue if arterial thromboembolic events, severe uncontrolled hypertension (despite antihypertensives), hypertensive crisis or encephalopathy, Grade 3 or 4 infusion-related reactions, urine protein >3g/24hrs, nephrotic syndrome, or GI perforation occurs. Impaired wound healing: withhold for 28 days prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Clinical deterioration in patients with Child-Pugh B or C cirrhosis (eg, new or worsening encephalopathy, ascites, hepatorenal syndrome). Permanently discontinue if posterior reversible encephalopathy syndrome develops. Monitor proteinuria by urine dipstick and/or urinary protein creatinine ratio. Monitor thyroid function. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 3 months after last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 2 months after last dose).